- Home
- FCNCA vs GMAB Comparison
FCNCA vs GMAB Comparison
Compare FCNCA & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCNCA | GMAB |
|---|---|---|
| Founded | 1898 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.0B | 20.3B |
| IPO Year | 1995 | 2008 |
Fundamental Metrics
Financial Performance| Metric | FCNCA | GMAB |
|---|---|---|
| Price | $2,194.11 | $33.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $2,199.64 | $39.56 |
| AVG Volume (30 Days) | 46.8K | ★ 2.8M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.43% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 97.95 | N/A |
| Revenue | ★ $9,541,000,000.00 | N/A |
| Revenue This Year | $3.43 | $17.85 |
| Revenue Next Year | N/A | $16.04 |
| P/E Ratio | $22.05 | ★ $1.90 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1,625.08 | $23.62 |
| 52 Week High | $2,296.30 | $35.43 |
Technical Indicators
Market Signals| Indicator | FCNCA | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 48.82 | 67.37 |
| Support Level | $2,049.02 | $30.68 |
| Resistance Level | $2,217.80 | $34.32 |
| Average True Range (ATR) | 43.10 | 0.63 |
| MACD | -11.72 | 0.07 |
| Stochastic Oscillator | 20.27 | 84.56 |
Price Performance
Historical ComparisonAbout FCNCA First Citizens BancShares Inc.
First Citizens is a US regional bank with total assets of around $236 billion as of March 31, 2026. Headquartered in Raleigh, North Carolina, First Citizens' largest markets are North Carolina, South Carolina, and California. The bank has a track record of acquiring troubled banks from the FDIC, such as Silicon Valley Bridge Bank in 2023, which doubled its asset base. First Citizens offers products and services across retail, commercial, wealth management, and railcar leasing. First Citizens derived over 95% of its earnings from banking and less than 5% from railcar leasing in 2025.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.